MedAssets (MDAS) 10-Q 7 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 25, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'MEDASSETS INC	'
Entity Central Index Key	'0001254419	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	60,986,125

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$0	$2,790
Accounts receivable, net of allowances of $2,539 and $2,568 as of March 31, 2014 and December 31, 2013, respectively	100,993	87,636
Deferred tax asset, current portion	2,764	4,535
Prepaid expenses and other current assets	24,049	24,059
Total current assets	127,806	119,020
Property and equipment, net	156,518	157,747
Other long term assets	'	'
Goodwill	1,027,847	1,027,847
Intangible assets, net	253,414	267,440
Other	41,034	41,695
Other long term assets	1,322,295	1,336,982
Total assets	1,606,619	1,613,749
Current liabilities	'	'
Accounts payable	19,586	24,066
Accrued revenue share obligation and rebates	71,125	77,398
Accrued payroll and benefits	18,277	41,587
Other accrued expenses	36,905	12,126
Deferred revenue, current portion	54,498	46,523
Current portion of notes payable	33,308	15,500
Current portion of finance obligation	273	255
Total current liabilities	233,972	217,455
Notes payable, less current portion	408,562	424,000
Bonds payable	325,000	325,000
Finance obligation, less current portion	8,698	8,781
Deferred revenue, less current portion	16,484	16,369
Deferred tax liability	116,902	121,083
Other long term liabilities	11,093	11,272
Total liabilities	1,120,711	1,123,960
Commitments and contingencies	'	'
Stockholders' equity	'	'
Common stock, $0.01 par value, 150,000,000 shares authorized; 61,176,000 and 61,740,000 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively	612	617
Additional paid-in capital	705,578	717,132
Accumulated deficit	-220,282	-227,960
Total stockholders' equity	485,908	489,789
Total liabilities and stockholders' equity	$1,606,619	$1,613,749

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Allowances on accounts receivable	$2,539	$2,568
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	61,176,000	61,740,000
Common stock, shares outstanding	61,176,000	61,740,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
Administrative fees, net	$76,246	$76,519
Other service fees	94,621	96,318
Total net revenue	170,867	172,837
Operating expenses:	'	'
Cost of revenue (inclusive of amortization expense of $424 and $598 for the three months ended March 31, 2014 and 2013, respectively)	37,431	34,268
Product development expenses	7,397	8,501
Selling and marketing expenses	15,193	13,742
General and administrative expenses	58,803	58,620
Restructuring, acquisition and integration-related expenses	1,697	8,030
Depreciation	11,540	9,177
Amortization of intangibles	14,026	16,501
Total operating expenses	146,087	148,839
Operating income	24,780	23,998
Other income (expense):	'	'
Interest (expense)	-11,173	-11,349
Other income	58	41
Income before income taxes	13,665	12,690
Income tax expense	5,987	4,986
Net income	$7,678	$7,704
Basic and diluted income per share:	'	'
Basic net income per share	$0.13	$0.13
Diluted net income per share	$0.12	$0.13
Weighted average shares-basic	60,648	59,006
Weighted average shares-diluted	61,681	60,404

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Amortization expense	$424	$598

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Balances at Dec. 31, 2013	$489,789	$617	$717,132	($227,960)
Balances, Shares at Dec. 31, 2013	'	61,740,000	'	'
Issuance of common stock from stock option and SSAR exercises and restricted stock issuances, net	1,756	2	1,754	'
Issuance of common stock from stock option and SSAR exercises and restricted stock issuances, net, Shares	'	185,000	'	'
Shares surrendered to pay taxes on vesting of restricted stock	-2,623	-1	-2,622	'
Shares surrendered to pay taxes on vesting of restricted stock, Shares	'	-109,000	'	'
Stock compensation expense	4,302	'	4,302	'
Repurchase of common stock	-16,061	-6	-16,055	'
Repurchase of common stock, Shares	-640,000	-640,000	'	'
Excess tax benefit from equity award exercises, net	1,067	'	1,067	'
Net income	7,678	'	'	7,678
Balances at Mar. 31, 2014	$485,908	$612	$705,578	($220,282)
Balances, Shares at Mar. 31, 2014	'	61,176,000	'	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities	'	'
Net income	$7,678	$7,704
Adjustments to reconcile income from continuing operations to net cash provided by operating activities:	'	'
Depreciation	11,964	9,775
Amortization of intangibles	14,026	16,501
Impairment of assets	'	2,015
(Gain) loss on sale of assets	-20	46
Noncash stock compensation expense	4,302	3,411
Excess tax benefit from exercise of equity awards	-1,382	-2,612
Amortization of debt issuance costs	943	953
Noncash interest expense, net	105	120
Deferred income tax benefit	-2,451	-474
Changes in assets and liabilities:	'	'
Accounts receivable	-13,357	2,986
Prepaid expenses and other assets	10	-3,798
Other long-term assets	452	20
Accounts payable	-4,691	-4,641
Accrued revenue share obligations and rebates	-6,273	-1,396
Accrued payroll and benefits	-23,310	-22,942
Other accrued expenses and long-term liabilities	21,647	12,098
Deferred revenue	8,090	-2,283
Cash provided by operating activities	17,733	17,483
Investing activities	'	'
Purchases of property, equipment and software, net	-1,748	-686
Capitalized software development costs	-8,383	-8,292
Cash used in investing activities	-10,131	-8,978
Financing activities	'	'
Borrowings from revolving credit facility	16,524	'
Repayment of notes payable	-13,875	-18,875
Repayment of revolving credit facility	-279	'
Repayment of finance obligation	-169	-169
Excess tax benefit from exercise of equity awards	1,382	2,612
Issuance of common stock, net of offering costs	1,756	2,725
Purchase of treasury shares, including shares surrendered for tax withholdings	-15,731	'
Cash used in financing activities	-10,392	-13,707
Net decrease in cash and cash equivalents	-2,790	-5,202
Cash and cash equivalents, beginning of period	2,790	13,734
Cash and cash equivalents, end of period	$0	$8,532

Business_Description_and_Basis

Business Description and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation	'
	1	BUSINESS DESCRIPTION AND BASIS OF PRESENTATION
	We provide technology-enabled products and services which together deliver solutions designed to reduce total cost of care, enhance operational efficiency, align clinical delivery with advance care coordination and improve revenue performance for hospitals, health systems and other ancillary healthcare providers. Our client-specific solutions are designed to efficiently analyze detailed information across the spectrum of cost, operations, clinical delivery and reimbursement. Our solutions integrate with existing operations and enterprise software systems of our clients and provide financial improvement with minimal upfront costs or capital expenditures. Our operations and clients are primarily located throughout the United States and to a limited extent, Canada.
	The accompanying unaudited condensed consolidated financial statements, and condensed consolidated balance sheet as of December 31, 2013, derived from audited financial statements, have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01 of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ materially from those estimates. Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2014.
	The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2013 included in our Form 10-K as filed with the SEC on March 3, 2014. These financial statements include the accounts of MedAssets, Inc. and our wholly owned subsidiaries. All significant intercompany accounts have been eliminated in consolidation.
	Use of Estimates
	The preparation of the financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations of the SEC, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ materially from those estimates. We believe that the estimates, assumptions and judgments involved in revenue recognition, allowances for doubtful accounts and returns, product development costs, share-based payments, business combinations, impairment of goodwill, intangible assets and long-lived assets, and accounting for income taxes have the greatest potential impact on our condensed consolidated financial statements.
	Cash and Cash Equivalents
	All of our highly liquid investments with original maturities of three months or less at the date of purchase are carried at cost which approximates fair value and are considered to be cash equivalents. Currently, our excess cash is voluntarily used to repay our swing line credit facility, if any, on a daily basis and applied against our revolving credit facility on a routine basis when our swing line credit facility is undrawn. In addition, we may periodically make voluntary repayments on our term loans.
	Cash and cash equivalents were zero and $2,790 as of March 31, 2014 and December 31, 2013, respectively. We had $26,245 and $10,000 outstanding on our revolving credit facility as of March 31, 2014 and December 31, 2013. In the event our cash balance is zero at the end of a period, any outstanding checks are recorded as accrued expenses.
	As of March 31, 2014, we reclassified approximately $14,846 of outstanding checks related to a book overdraft into other accrued expenses on the condensed consolidated balance sheet. This book overdraft amount has been included in operating activities within the condensed consolidated statement of cash flows. See Note 5 for immediately available cash under our revolving credit facility.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2014
Accounting Changes And Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	2	RECENT ACCOUNTING PRONOUNCEMENTS
	Income Taxes
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update relating to the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. This update amends existing GAAP that required in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. We adopted this update on January 1, 2014.
	Obligations Resulting from Joint and Several Liability Arrangements
	In February 2013, the FASB issued guidance for the recognition, measurement and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of the guidance is fixed at the reporting date. Examples of obligations within the scope of this update include debt arrangements, other contractual obligations and settled litigation and judicial rulings. The guidance requires an entity to measure such obligations as the sum of the amount that the reporting entity agreed to pay on the basis of its arrangement among its co-obligors plus additional amounts the reporting entity expects to pay on behalf of its co-obligors. The guidance in the update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. The update is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. We adopted this update on January 1, 2014.

Restructuring_Acquisition_and_

Restructuring, Acquisition and Integration-Related Expenses	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Restructuring, Acquisition and Integration-Related Expenses	'
	3	RESTRUCTURING, ACQUISITION AND INTEGRATION-RELATED EXPENSES
	Restructuring Activities
	Restructuring charges consist of exit costs and other costs associated with the reorganization of our operations, including employee termination costs, lease contract termination costs, impairment of assets, and any other qualifying exit costs. Costs associated with exit or disposal activities are recorded when the liability is incurred or when such costs are deemed probable and estimable and represent management’s best estimate.
	In January 2014, our management approved and initiated a plan to restructure our operations resulting in certain workforce changes within the Company that resulted in costs of approximately $1,697. During the three months ended March 31, 2014 and 2013, we expensed restructuring and exit and integration-related costs of approximately $1,697 and $8,030, respectively. These costs are included within the restructuring, acquisition and integration-related expenses line on the accompanying condensed consolidated statements of operations. As of March 31, 2014, cash payments were made of approximately $1,382 and we had approximately $935 included in current liabilities for these employee-related costs that we expect to pay over the next twelve months.

Deferred_Revenue

Deferred Revenue	3 Months Ended
	Mar. 31, 2014
Revenue Recognition [Abstract]	'
Deferred Revenue	'
	4	DEFERRED REVENUE
	Deferred revenue consists of unrecognized revenue related to advanced client billing or client payments received prior to revenue being realized and earned. Substantially all of our deferred revenue consists of: (i) deferred administrative fees, net; (ii) deferred service fees; (iii) deferred software and implementation fees; and (iv) other deferred fees, including receipts for our annual customer and vendor meeting prior to the event.
	The following table summarizes the deferred revenue categories and balances as of:
			March 31,		December 31,
			2014		2013
	Software and implementation fees		$	32,276	$	27,393
	Service fees			24,617		22,363
	Administrative fees			6,662		10,935
	Other fees			7,427		2,201
	Deferred revenue, total			70,982		62,892
	Less: Deferred revenue, current portion			(54,498)		(46,523)
	Deferred revenue, non-current portion		$	16,484	$	16,369
	As of March 31, 2014 and December 31, 2013, deferred revenue included in our condensed consolidated balance sheets that was contingent upon meeting performance targets was $2,879 and $6,516, respectively. Advance billings on arrangements that include contingent performance targets are recorded in accounts receivable and deferred revenue when billed. Only certain contingent performance targets are billed in advance of meeting the target as determined by the customer arrangement.

Notes_and_Bonds_Payable

Notes and Bonds Payable	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Notes and Bonds Payable	'
	5. NOTES AND BONDS PAYABLE
	The balances of our notes and bonds payable are summarized as follows as of:
			March 31,		December 31,
			2014		2013
	Term A facility		$	234,375	$	237,500
	Term B facility			181,250		192,000
	Revolving credit facility			26,245		10,000
	Total notes payable			441,870		439,500
	Bonds payable			325,000		325,000
	Total notes and bonds payable			766,870		764,500
	Less: current portions			(33,308)		(15,500)
	Total long-term notes and bonds payable		$	733,562	$	749,000
	Notes Payable
	As of March 31, 2014, our long-term notes payable consists of a Term A Facility, a Term B Facility and a revolving credit facility, each with an outstanding balance of $234,375, $181,250 and $26,245 (inclusive of our swing line balance of $16,245), respectively. We have classified the balance of the swing line component of our revolving credit facility as a current liability because under our auto-borrowing plan all excess cash on hand is used to repay the swing line component on a daily basis, and the swing line component is expected to be repaid over the next twelve months. We have classified the remaining $10,000 of the outstanding balance on our revolving credit facility as a long term liability given the maturity date of December 13, 2017. This resulted in approximately $172,755 of availability under our revolving credit facility (after giving effect to $1,000 of outstanding but undrawn letters of credit on such date) as of March 31, 2014. During the three months ended March 31, 2014, we made scheduled principal payments of $3,875 on our Term A Facility and Term B Facility in addition to $10,000 in voluntary prepayments on our Term B Facility. The applicable weighted average interest rates (inclusive of the applicable bank margin) on our Term A Facility, Term B Facility and Revolving Credit Facility at March 31, 2014 were 2.50%, 4.00% and 2.49%, respectively.
	We are a party to a credit agreement with JP Morgan Chase Bank, N.A and other financial institutions named therein, dated December 13, 2012 (the “Credit Agreement”). The Credit Agreement contains certain customary negative covenants, including but not limited to, limitations on the incurrence of debt, limitations on liens, limitations on fundamental changes, limitations on asset sales and sale leasebacks, limitations on investments, limitations on dividends or distributions on, or redemptions of, equity interests, limitations on prepayments or redemptions of unsecured or subordinated debt, limitations on negative pledge clauses, limitations on transactions with affiliates and limitations on changes to the Company’s fiscal year. The Credit Agreement also includes maintenance covenants of maximum ratios of consolidated total indebtedness (subject to certain adjustments) to consolidated EBITDA (subject to certain adjustments) and minimum cash interest coverage ratios. The Credit Agreement contains certain customary representations and warranties, affirmative covenants and events of default, including but not limited to payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to certain indebtedness, certain events of insolvency or bankruptcy, material judgments, certain events under ERISA, actual or asserted failures of any guaranty or security document supporting the credit agreement to be in full force and effect and changes of control. The Company was in compliance with these covenants as of March 31, 2014. We are also required to prepay our debt obligations based on an excess cash flow calculation for the applicable fiscal year which is determined in accordance with the terms of the Credit Agreement. Our current portion of notes payable does not include an amount with respect to any 2014 excess cash flow payment. We will reclassify a portion of our long-term notes payable to a current classification at such time that any 2014 excess cash flow payment becomes estimable. We will be required to make any necessary cash flow payment within the first quarter of 2015.
	All of the Company’s obligations under the Credit Agreement are unconditionally guaranteed by each of the Company’s existing and subsequently acquired or organized wholly-owned restricted subsidiaries, except that the following subsidiaries do not and will not provide guarantees: (a) unrestricted subsidiaries, (b) subsidiaries with tangible assets and revenues each having a value of less than 2.5% of the consolidated tangible assets and consolidated revenues of the Company (provided that all such immaterial subsidiaries, on a consolidated basis, shall not account for more than 5.0% of the consolidated EBITDA of the Company), (c) any subsidiary prohibited by applicable law, rule or regulation from providing a guarantee or which would require governmental (including regulatory) consent or approval or which would result in adverse tax consequences and (d) not-for-profit subsidiaries.
	All of the Company’s obligations under the Credit Agreement are secured by substantially all of the Company’s assets and the assets of each guarantor (subject to certain exceptions), including, but not limited to (1) a perfected pledge of all of the equity securities of each direct wholly owned restricted subsidiary of the Company and of each subsidiary guarantor (which pledge, in the case of any foreign subsidiary, is limited to 65% of the equity securities of such foreign subsidiary) and (2) perfected security interests in, and mortgages on, substantially all tangible and intangible personal property and material fee-owned real property of the Company and each subsidiary guarantor (including but not limited to accounts receivable, inventory, equipment, general intangibles (including contract rights), investment property, intellectual property, material intercompany notes and proceeds of the foregoing).
	Loans under the Credit Agreement must be prepaid under certain circumstances, including with proceeds from certain future debt issuances, asset sales and a portion of excess cash flow for the applicable fiscal year. Loans under the Credit Agreement may be voluntarily prepaid at any time, subject to customary LIBOR breakage costs.
	Bonds Payable
	In November 2010, we closed the offering of an aggregate principal amount of $325,000 of senior notes due 2018 (the “Notes”) in a private placement (the “Notes Offering”). In October 2011, our Notes were registered under the Securities Act of 1933, as amended. The Notes are guaranteed on a senior unsecured basis by each of our existing domestic subsidiaries and each of our future domestic restricted subsidiaries in each case that guarantees our obligations under the credit agreement. Each of the subsidiary guarantors is 100% owned by us; the guarantees by the subsidiary guarantors are full and unconditional; the guarantees by the subsidiary guarantors are joint and several; we have no independent assets or operations; and any subsidiaries of ours other than the subsidiary guarantors are minor. The Notes and the guarantees are senior unsecured obligations of the Company and the subsidiary guarantors, respectively.
	The Notes were issued pursuant to an indenture dated as of November 16, 2010 (the “Indenture”) among the Company, its subsidiary guarantors and Wells Fargo Bank, N.A., as trustee. Pursuant to the Indenture, the Notes will mature on November 15, 2018 and bear 8% annual interest. Interest on the Notes is payable semi-annually in arrears on May 15 and November 15 of each year, beginning on May 15, 2011.
	The Indenture contains certain customary negative covenants, including but not limited to, limitations on the incurrence of debt, limitations on liens, limitations on consolidations or mergers, limitations on asset sales, limitations on certain restricted payments and limitations on transactions with affiliates. The Indenture does not contain any significant restrictions on the ability of the Company or any subsidiary guarantor to obtain funds from the Company or any other subsidiary guarantor by dividend or loan. The Indenture also contains customary events of default. The Company was in compliance with these covenants as of March 31, 2014.
	The Company has the option to redeem the Notes as follows: (i) at any time prior to November 15, 2014, the Company may redeem all or part of the Notes at a redemption price equal to 100% of the principal amount plus the applicable premium (as defined in the Indenture); and (ii) on and after November 15, 2014, the Company may redeem all or a part of the Notes, at the following redemption prices:
	Year		Percentage
	2014			104%
	2015			102%
	2016 and thereafter			100%
	The Notes also contain a redemption feature that would require the repurchase of 101% of the aggregate principal amount plus accrued and unpaid interest at the option of the holders upon a change in control.
	As of March 31, 2014, the Company’s 8% senior notes due 2018 were trading at 107.0% of par value (Level 1).
	Debt Issuance Costs
	As of March 31, 2014, we had approximately $16,323 of debt issuance costs related to our credit agreement and Notes which will be amortized into interest expense generally using the effective interest method until the applicable maturity date. For the three months ended March 31, 2014 and 2013, we recognized $943 and $953, respectively, in interest expense related to the amortization of debt issuance costs.
	Debt Maturity Table
	The following table summarizes our stated debt maturities and scheduled principal repayments as of March 31, 2014:
	Year		Term A		Term B		Revolving		Senior		Total
			Facility		Facility		Credit		Unsecured
							Facility		Notes
	2014		$	9,375	$	2,250	$	16,245	$	-	$	27,870	(1)
	2015			18,750		3,000		-		-		21,750
	2016			25,000		3,000		-		-		28,000
	2017			181,250		3,000		10,000		-		194,250
	2018			-		3,000		-		325,000		328,000
	Thereafter			-		167,000		-		-		167,000
			$	234,375	$	181,250	$	26,245	$	325,000	$	766,870
		-1	Represents the remaining quarterly principal payments due during the fiscal year ending December 31, 2014 and the balance of the swing line component of our revolving credit facility.
	Total interest paid (net of amounts capitalized) on our notes and bonds payable during the three months ended March 31, 2014 and 2013 was approximately $3,484 and $5,932, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	6	COMMITMENTS AND CONTINGENCIES
	Performance Targets
	In the ordinary course of contracting with our clients, we may agree to make some or all of our fees contingent upon the client’s achievement of financial improvement targets from the use of our services and software. These contingent fees are not recognized as revenue until the client confirms achievement of the performance targets. We generally receive client acceptance as and when the performance targets are achieved. If we invoice contingent fees prior to client confirmation that a performance target has been achieved, we record invoiced contingent fees as deferred revenue on our condensed consolidated balance sheet. Often, recognition of this revenue occurs in periods subsequent to the recognition of the associated costs.
	Legal Proceedings
	From time to time, we become involved in legal proceedings arising in the ordinary course of business. As of March 31, 2014, we are not presently involved in any legal proceedings, the outcome of which, if determined adversely to us, would have a material adverse effect on our business, operating results or financial condition.

Stockholders_Equity_and_ShareB

Stockholders' Equity and Share-Based Compensation	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Stockholders' Equity and Share-Based Compensation	'
	7	STOCKHOLDERS’ EQUITY AND SHARE-BASED COMPENSATION
	Common Stock
	During the three months ended March 31, 2014, we issued approximately 211,000 shares of common stock in connection with employee stock option exercises, stock-settled stock appreciation rights (“SSARs”) exercises and the vesting of restricted stock units (“RSUs”) for net exercise proceeds of $1,756.
	During the three months ended March 31, 2014, approximately 26,000 shares of restricted common stock were forfeited.
	During the three months ended March 31, 2014, we received approximately 109,000 restricted shares that were surrendered from equity awards holders to settle their associated minimum statutory tax liability of $2,623 from shares that vested during the year.
	Repurchase of Common Stock
	On February 26, 2014, our Board of Directors authorized a share repurchase program of up to $75,000 of our common stock. The following table shows the amount and cost of shares of common stock we repurchased for the three months ended March 31, 2014 under the share repurchase program. The repurchased shares have not been retired and constitute authorized but unissued shares.
			Three months ended March 31,
			2014		2013
	Number of shares repurchased			640,000		-
	Cost of shares repurchased(1)		$	16,061	$	-
		-1	Our share repurchase program required a three-day cash settlement period with our broker. We made purchases during the last three days of March 2014 amounting to 120,000 shares totaling $2,953, which were settled in April 2014. The cost of these shares is included in other accrued expenses on our condensed consolidated balance sheet as of March 31, 2014.
	Share-Based Compensation
	As of March 31, 2014, we had restricted common stock, RSUs, SSARs and common stock option equity awards outstanding under three share-based compensation plans. As of March 31, 2014, we had approximately 4,800,000 shares reserved (inclusive of equity award forfeitures) and available for grant under the 2008 MedAssets, Inc. Long-Term Performance Incentive Plan (“LTPIP”).
	The total share-based compensation expense related to equity awards was $4,302 and $3,411 for the three months ended March 31, 2014 and 2013, respectively. The total income tax benefit recognized in the condensed consolidated statement of operations for share-based compensation arrangements related to equity awards was $1,602 and $1,280 for the three months ended March 31, 2014 and 2013, respectively. There were no capitalized share-based compensation expenses during the three months ended March 31, 2014.
	Total share-based compensation expense (inclusive of restricted common stock, RSUs, SSARs and common stock options) for the three months ended March 31, 2014 and 2013 as reflected in our condensed consolidated statements of operations is as follows:
			Three Months Ended March 31,
			2014		2013
	Cost of revenue		$	1,166	$	713
	Product development			244		118
	Selling and marketing			527		379
	General and administrative			2,365		2,201
	Total share-based compensation expense		$	4,302	$	3,411
	Employee Stock Purchase Plan
	In 2010, we established the MedAssets, Inc. Employee Stock Purchase Plan (the “Plan”). Under the Plan, eligible employees may purchase shares of our common stock at a discounted price through payroll deductions. The price per share of the common stock sold to participating employees will be 95% of the fair market value of our common stock on the applicable purchase date. The Plan requires that all stock purchased be held by participants for a period of 18 months from the purchase date. A total of 500,000 shares of our common stock are authorized for purchase under the Plan. For the three months ended March 31, 2014 and 2013, we purchased approximately 11,000 shares and 11,700 shares of our common stock under the Plan which amounted to approximately $253 and $205, respectively.
	Equity Award Grants
	Information regarding equity awards for the three months ended March 31, 2014 is as follows:
	Restricted Stock Unit Equity Awards
	In February 2014, our Compensation Committee of our Board of Directors approved an equity grant for certain eligible employees consisting of service-based and performance-based RSUs. The purpose of the equity grant is to assist the Company in attracting, retaining, motivating, and rewarding certain individuals of the Company. The equity grant is intended to promote the creation of long-term value for stockholders of the Company by closely aligning the interests of such individuals with those of the stockholders. The total approved equity grant amounted to 1,218,826 RSUs with a grant date fair value of $25.06 per share and was comprised of: (i) 63,355 service-based RSUs that vest ratably each month through December 31, 2014; (ii) 469,011 service-based RSUs that vest annually over three years of continuous service with the first annual vest date beginning on March 1, 2015; (iii) 343,230 performance-based RSUs using a net revenue performance metric that vest annually over three years of continuous service with the first annual vest date beginning on March 1, 2015 provided the performance metric is achieved; and (iv) 343,230 performance-based RSUs using an adjusted EBITDA performance metric that vest annually over three years of continuous service with the first annual vest date beginning on March 1, 2015 provided the performance metric is achieved.
	The measurement period for the net revenue performance-based awards is from January 1, 2014 through December 31, 2014. The net revenue performance metric is based on the achievement of an established net revenue target. The Company must achieve a minimum threshold of net revenue before any performance-based RSUs begin vesting. The equity award holders have an opportunity to earn between 50% and 100% of the performance-based equity awards once the minimum threshold has been met. If the minimum threshold is not met, the equity award holders will forfeit those awards.
	The measurement period for the adjusted EBITDA performance-based awards is from January 1, 2014 through December 31, 2014. The adjusted EBITDA performance metric is based on the achievement of an established adjusted EBITDA target. The Company must achieve a minimum threshold of adjusted EBITDA before any performance-based RSUs begin vesting. The equity award holders have an opportunity to earn between 50% and 100% of the performance-based equity awards once the minimum threshold has been met. If the minimum threshold is not met, the equity award holders will forfeit those awards.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	8	INCOME TAXES
	Income tax expense recorded during the three months ended March 31, 2014 and 2013 reflected an effective income tax rate of 43.8% and 39.3%, respectively.

Income_Per_Share

Income Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Income Per Share	'
	9	INCOME PER SHARE
	We calculate earnings per share (or “EPS”) in accordance with the GAAP relating to earnings per share. Basic EPS is calculated by dividing reported net income by the weighted-average number of common shares outstanding for the reported period following the two-class method. Diluted EPS reflects the potential dilution that could occur if our stock options, SSARs, unvested restricted stock, RSUs and shares that were purchasable pursuant to our employee stock purchase plan were exercised and converted into our common shares during the reporting periods.
	A reconciliation of basic and diluted weighted average shares outstanding for basic and diluted EPS for the three months ended March 31, 2014 and 2013 is as follows:
			Three Months Ended March 31,
			2014		2013
	Numerator for Basic and Diluted Income Per Share:
	Net income			7,678		7,704
	Denominator for basic income per share weighted average shares			60,648,000		59,006,000
	Effect of dilutive securities:
	Stock options			285,000		719,000
	SSARs			327,000		345,000
	Restricted stock and RSUs			421,000		334,000
	Denominator for diluted income per share—adjusted weighted average shares and assumed conversions			61,681,000		60,404,000
	Basic income per share:
	Basic net income from continuing operations		$	0.13	$	0.13
	Diluted net income per share:
	Diluted net income from continuing operations		$	0.12	$	0.13
	During the three months ended March 31, 2014 and 2013, the effect of certain dilutive securities have been excluded because the impact is anti-dilutive as a result of certain securities being “out of the money” with strike prices greater than the average market price during the periods presented.
	The following table provides a summary of those potentially dilutive securities that have been excluded from the above calculation of diluted EPS:
			Three Months Ended March 31,
			2014		2013
	SSARs			-		63,000

Segment_Information

Segment Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	10. SEGMENT INFORMATION
	We manage our business through two reportable business segments, Spend and Clinical Resource Management (or “SCM”) and Revenue Cycle Management (or “RCM”).
		—		Spend and Clinical Resource Management. Our SCM segment provides a comprehensive suite of technology-enabled services that help our clients manage their expense categories. Our solutions lower supply and medical device pricing and utilization by managing the procurement process through our group purchasing organization (“GPO”) portfolio of contracts, consulting services and business intelligence tools.
		—		Revenue Cycle Management. Our RCM segment provides a comprehensive suite of products and services spanning the hospital revenue cycle workflow — from patient access and financial responsibility, charge capture and integrity, pricing analysis, claims processing and denials management, payor contract management, revenue recovery and accounts receivable services. Our workflow solutions, together with our data management, compliance and audit tools, increase revenue capture and cash collections, reduce accounts receivable balances and increase regulatory compliance.
	GAAP relating to segment reporting defines reportable segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing financial performance. The guidance indicates that financial information about segments should be reported on the same basis as that which is used by the chief operating decision maker in the analysis of performance and allocation of resources. Management of the Company, including our chief operating decision maker, uses what we refer to as Segment Adjusted EBITDA as its primary measure of profit or loss to assess segment performance and to determine the allocation of resources. We define Segment Adjusted EBITDA as segment net income (loss) before net interest expense, income tax expense (benefit), depreciation and amortization (“EBITDA”) as adjusted for other non-recurring, non-cash or non-operating items. Our chief operating decision maker uses Segment Adjusted EBITDA to facilitate a comparison of our operating performance on a consistent basis from period to period. Segment Adjusted EBITDA includes expenses associated with sales and marketing, general and administrative and product development activities specific to the operation of the segment. General and administrative corporate expenses that are not specific to the segments are not included in the calculation of Segment Adjusted EBITDA. These expenses include the costs to manage our corporate offices, interest expense on our credit facilities and expenses related to being a publicly-held company. All reportable segment revenues are presented net of inter-segment eliminations and represent revenues from external clients.
	The following tables present Segment Adjusted EBITDA and financial position information as utilized by our chief operating decision maker. A reconciliation of Segment Adjusted EBITDA to consolidated net income is included. General corporate expenses are included in the “Corporate” line item. “RCM” represents the Revenue Cycle Management segment and “SCM” represents the Spend and Clinical Resource Management segment. Other assets and liabilities are included to provide a reconciliation to total assets and total liabilities.
	The following tables represent our results of operations, by segment, for the three months ended March 31, 2014 and 2013:
			Three Months Ended
			March 31,
			2014		2013
	Revenue:
	SCM
	Gross administrative fees(1)		$	126,361	$	120,636
	Revenue share obligation(1)			(50,115)		(44,117)
	Net administrative fees			76,246		76,519
	Other service fees(2)			32,371		32,989
	Total SCM net revenue			108,617		109,508
	RCM
	Revenue cycle technology			44,193		43,381
	Revenue cycle services			18,057		19,948
	Total RCM net revenue			62,250		63,329
	Total net revenue			170,867		172,837
	Operating expenses:
	SCM			76,443		81,689
	RCM			56,975		55,693
	Corporate			12,669		11,457
	Total operating expenses			146,087		148,839
	Operating income (loss):
	SCM			32,174		27,819
	RCM			5,275		7,636
	Corporate			(12,669)		(11,457)
	Total operating income			24,780		23,998
	Interest expense			(11,173)		(11,349)
	Other income			58		41
	Income before income taxes			13,665		12,690
	Income tax expense			5,987		4,986
	Net income		$	7,678	$	7,704
	Segment Adjusted EBITDA
	SCM		$	49,950	$	53,712
	RCM			13,401		14,690
	Total Segment Adjusted EBITDA		$	63,351	$	68,402
	Corporate			(6,634)		(6,756)
	Total Adjusted EBITDA(1)		$	56,717	$	61,646
		-1	These are non-GAAP measures. See “Use of Non-GAAP Financial Measures” section for additional information.
		-2	Other service fees primarily consists of consulting, services and technology fees.
			Three Months Ended
			March 31,
			2014		2013
	Capital expenditures(1):
	SCM		$	3,283	$	1,857
	RCM			5,499		5,149
	Corporate			1,349		1,972
	Total		$	10,131	$	8,978
		-1	Capital expenditures consist of purchases of property and equipment and capitalized software development costs (internal and external use).
			March 31,		March 31,
			2014		2013
	Financial Position:
	Accounts receivable, net
	SCM		$	50,510	$	45,613
	RCM			50,348		48,047
	Corporate			135		-
	Total accounts receivable, net			100,993		93,660
	Other assets
SCM			943,587		995,161
RCM			496,577		489,967
Corporate			65,462		84,512
Total other assets			1,505,626		1,569,640
Total assets		$	1,606,619	$	1,663,300
SCM accrued revenue share obligation		$	71,125	$	72,878
Deferred revenue
SCM			27,892		26,831
RCM			43,090		41,035
Total deferred revenue			70,982		67,866
Notes payable			441,870		541,125
Bonds payable			325,000		325,000
Other liabilities
SCM			20,489		19,137
RCM			18,273		28,053
Corporate			172,972		160,206
Total other liabilities			211,734		207,396
Total liabilities		$	1,120,711	$	1,214,265
GAAP for segment reporting requires that the total of the reportable segments’ measures of profit or loss be reconciled to the Company’s consolidated operating results. The following table reconciles Segment Adjusted EBITDA to consolidated net income for the three months ended March 31, 2014 and 2013:
		Three Months Ended March 31,
		2014		2013
SCM Adjusted EBITDA		$	49,950	$	53,712
RCM Adjusted EBITDA			13,401		14,690
Total Segment Adjusted EBITDA			63,351		68,402
Depreciation			(8,262)		(6,476)
Depreciation (included in cost of revenue)			(424)		(598)
Amortization of intangibles			(14,026)		(16,501)
Income tax expense			(16,390)		(13,910)
Share-based compensation expense(1)			(2,098)		(1,398)
Restructuring, acquisition and integration-related expenses(2)			(1,131)		(8,030)
Total reportable segment net income			21,020		21,489
Corporate net loss			(13,342)		(13,785)
Consolidated net income		$	7,678	$	7,704
	-1	Represents non-cash share-based compensation to both employees and directors. We believe excluding this non-cash expense allows us to compare our operating performance without regard to the impact of share-based compensation, which varies from period to period based on amount and timing of grants.
	-2	Represents the amount attributable to restructuring, acquisition and integration-related costs which may include costs such as severance, retention, salaries relating to redundant positions, certain performance-related salary-based compensation, operating infrastructure costs and facility consolidation costs.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	11	FAIR VALUE MEASUREMENTS
	We measure fair value for financial instruments when a valuation is necessary, such as for impairment of long-lived and indefinite-lived assets when indicators of impairment exist in accordance with GAAP for fair value measurements and disclosures. This defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measures required under other accounting pronouncements, but does not change existing guidance as to whether or not an instrument is carried at fair value.
	In estimating our fair value disclosures for financial instruments, we use the following methods and assumptions:
		—	Cash and cash equivalents. The carrying value reported in the condensed consolidated balance sheets for these items approximates fair value due to the high credit standing of the financial institutions holding these items and their liquid nature;
		—	Accounts receivable, net. The carrying value reported in the condensed consolidated balance sheets is net of allowances for doubtful accounts which includes a degree of counterparty non-performance risk;
		—	Accounts payable and current liabilities. The carrying value reported in the condensed consolidated balance sheets for these items approximates fair value, which is the likely amount for which the liability with short settlement periods would be transferred to a market participant with a similar credit standing as the Company;
		—	Notes payable. The carrying value of our long-term notes payable reported in the condensed consolidated balance sheets approximates fair value since they bear interest at variable rates. Refer to Note 5 for further information; and
		—	Bonds payable. The carrying value of our long-term bonds payable reported in the condensed consolidated balance sheets approximates fair value. Refer to Note 5 for further information.

Related_Party_Transaction

Related Party Transaction	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transaction	'
	12	RELATED PARTY TRANSACTION
	We have an agreement with John Bardis, our chief executive officer, for the use of an airplane owned by JJB Aviation, LLC, a limited liability company, owned by Mr. Bardis. We pay Mr. Bardis at market-based rates for the use of the airplane for business purposes. The audit committee of the board of directors reviews such usage of the airplane annually. During the three months ended March 31, 2014 and 2013, we incurred charges of $378 and $587, respectively, related to transactions with Mr. Bardis.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	13	SUBSEQUENT EVENTS
	We have evaluated subsequent events for recognition or disclosure in the condensed consolidated financial statements filed on Form 10-Q with the SEC and no events have occurred that require disclosure.

Business_Description_and_Basis1

Business Description and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The preparation of the financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations of the SEC, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ materially from those estimates. We believe that the estimates, assumptions and judgments involved in revenue recognition, allowances for doubtful accounts and returns, product development costs, share-based payments, business combinations, impairment of goodwill, intangible assets and long-lived assets, and accounting for income taxes have the greatest potential impact on our condensed consolidated financial statements.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	All of our highly liquid investments with original maturities of three months or less at the date of purchase are carried at cost which approximates fair value and are considered to be cash equivalents. Currently, our excess cash is voluntarily used to repay our swing line credit facility, if any, on a daily basis and applied against our revolving credit facility on a routine basis when our swing line credit facility is undrawn. In addition, we may periodically make voluntary repayments on our term loans.
	Cash and cash equivalents were zero and $2,790 as of March 31, 2014 and December 31, 2013, respectively. We had $26,245 and $10,000 outstanding on our revolving credit facility as of March 31, 2014 and December 31, 2013. In the event our cash balance is zero at the end of a period, any outstanding checks are recorded as accrued expenses.
	As of March 31, 2014, we reclassified approximately $14,846 of outstanding checks related to a book overdraft into other accrued expenses on the condensed consolidated balance sheet. This book overdraft amount has been included in operating activities within the condensed consolidated statement of cash flows. See Note 5 for immediately available cash under our revolving credit facility.

Deferred_Revenue_Tables

Deferred Revenue (Tables)	3 Months Ended
	Mar. 31, 2014
Revenue Recognition [Abstract]	'
Summary of Deferred Revenue	'
	The following table summarizes the deferred revenue categories and balances as of:
		March 31,		December 31,
		2014		2013
	Software and implementation fees	$	32,276	$	27,393
	Service fees		24,617		22,363
	Administrative fees		6,662		10,935
	Other fees		7,427		2,201
	Deferred revenue, total		70,982		62,892
	Less: Deferred revenue, current portion		(54,498)		(46,523)
	Deferred revenue, non-current portion	$	16,484	$	16,369

Notes_and_Bonds_Payable_Tables

Notes and Bonds Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Summary of Notes Payable	'
	The balances of our notes and bonds payable are summarized as follows as of:
		March 31,		December 31,
		2014		2013
	Term A facility	$	234,375	$	237,500
	Term B facility		181,250		192,000
	Revolving credit facility		26,245		10,000
	Total notes payable		441,870		439,500
	Bonds payable		325,000		325,000
	Total notes and bonds payable		766,870		764,500
	Less: current portions		(33,308)		(15,500)
	Total long-term notes and bonds payable	$	733,562	$	749,000
Percentage of Redemption Prices	'
	The Company has the option to redeem the Notes as follows: (i) at any time prior to November 15, 2014, the Company may redeem all or part of the Notes at a redemption price equal to 100% of the principal amount plus the applicable premium (as defined in the Indenture); and (ii) on and after November 15, 2014, the Company may redeem all or a part of the Notes, at the following redemption prices:
	Year	Percentage
	2014		104%
	2015		102%
	2016 and thereafter		100%
Debt Maturities and Scheduled Principal Repayments	'
	The following table summarizes our stated debt maturities and scheduled principal repayments as of March 31, 2014:
	Year	Term A		Term B		Revolving		Senior		Total
		Facility		Facility		Credit		Unsecured
						Facility		Notes
	2014	$	9,375	$	2,250	$	16,245	$	-	$	27,870	(1)
	2015		18,750		3,000		-		-		21,750
	2016		25,000		3,000		-		-		28,000
	2017		181,250		3,000		10,000		-		194,250
	2018		-		3,000		-		325,000		328,000
	Thereafter		-		167,000		-		-		167,000
		$	234,375	$	181,250	$	26,245	$	325,000	$	766,870

Stockholders_Equity_and_ShareB1

Stockholders' Equity and Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Summary of Cost of Shares Purchased	'
	The following table shows the amount and cost of shares of common stock we repurchased for the three months ended March 31, 2014 under the share repurchase program. The repurchased shares have not been retired and constitute authorized but unissued shares.
			Three months ended March 31,
			2014		2013
	Number of shares repurchased			640,000		-
	Cost of shares repurchased(1)		$	16,061	$	-
		-1	Our share repurchase program required a three-day cash settlement period with our broker. We made purchases during the last three days of March 2014 amounting to 120,000 shares totaling $2,953, which were settled in April 2014. The cost of these shares is included in other accrued expenses on our condensed consolidated balance sheet as of March 31, 2014.
Summary of Total Share-Based Compensation Expense	'
	Total share-based compensation expense (inclusive of restricted common stock, RSUs, SSARs and common stock options) for the three months ended March 31, 2014 and 2013 as reflected in our condensed consolidated statements of operations is as follows:
			Three Months Ended March 31,
			2014		2013
	Cost of revenue		$	1,166	$	713
	Product development			244		118
	Selling and marketing			527		379
	General and administrative			2,365		2,201
	Total share-based compensation expense		$	4,302	$	3,411

Income_Per_Share_Tables

Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Reconciliation of Basic and Diluted Weighted Average Shares Outstanding	'
	A reconciliation of basic and diluted weighted average shares outstanding for basic and diluted EPS for the three months ended March 31, 2014 and 2013 is as follows:
		Three Months Ended March 31,
		2014		2013
	Numerator for Basic and Diluted Income Per Share:
	Net income		7,678		7,704
	Denominator for basic income per share weighted average shares		60,648,000		59,006,000
	Effect of dilutive securities:
	Stock options		285,000		719,000
	SSARs		327,000		345,000
	Restricted stock and RSUs		421,000		334,000
	Denominator for diluted income per share—adjusted weighted average shares and assumed conversions		61,681,000		60,404,000
	Basic income per share:
	Basic net income from continuing operations	$	0.13	$	0.13
	Diluted net income per share:
	Diluted net income from continuing operations	$	0.12	$	0.13
Summary of Potentially Dilutive Securities	'
	The following table provides a summary of those potentially dilutive securities that have been excluded from the above calculation of diluted EPS:
		Three Months Ended March 31,
		2014		2013
	SSARs		-		63,000

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Financial Information of Business Segments	'
	The following tables represent our results of operations, by segment, for the three months ended March 31, 2014 and 2013:
			Three Months Ended
			March 31,
			2014		2013
	Revenue:
	SCM
	Gross administrative fees(1)		$	126,361	$	120,636
	Revenue share obligation(1)			(50,115)		(44,117)
	Net administrative fees			76,246		76,519
	Other service fees(2)			32,371		32,989
	Total SCM net revenue			108,617		109,508
	RCM
	Revenue cycle technology			44,193		43,381
	Revenue cycle services			18,057		19,948
	Total RCM net revenue			62,250		63,329
	Total net revenue			170,867		172,837
	Operating expenses:
	SCM			76,443		81,689
	RCM			56,975		55,693
	Corporate			12,669		11,457
	Total operating expenses			146,087		148,839
	Operating income (loss):
	SCM			32,174		27,819
	RCM			5,275		7,636
	Corporate			(12,669)		(11,457)
	Total operating income			24,780		23,998
	Interest expense			(11,173)		(11,349)
	Other income			58		41
	Income before income taxes			13,665		12,690
	Income tax expense			5,987		4,986
	Net income		$	7,678	$	7,704
	Segment Adjusted EBITDA
	SCM		$	49,950	$	53,712
	RCM			13,401		14,690
	Total Segment Adjusted EBITDA		$	63,351	$	68,402
	Corporate			(6,634)		(6,756)
	Total Adjusted EBITDA(1)		$	56,717	$	61,646
		-1	These are non-GAAP measures. See “Use of Non-GAAP Financial Measures” section for additional information.
		-2	Other service fees primarily consists of consulting, services and technology fees.
			Three Months Ended
			March 31,
			2014		2013
	Capital expenditures(1):
	SCM		$	3,283	$	1,857
	RCM			5,499		5,149
	Corporate			1,349		1,972
	Total		$	10,131	$	8,978
		-1	Capital expenditures consist of purchases of property and equipment and capitalized software development costs (internal and external use).
			March 31,		March 31,
			2014		2013
	Financial Position:
	Accounts receivable, net
	SCM		$	50,510	$	45,613
	RCM			50,348		48,047
	Corporate			135		-
	Total accounts receivable, net			100,993		93,660
	Other assets
	SCM			943,587		995,161
	RCM			496,577		489,967
	Corporate			65,462		84,512
	Total other assets			1,505,626		1,569,640
	Total assets		$	1,606,619	$	1,663,300
	SCM accrued revenue share obligation		$	71,125	$	72,878
Deferred revenue
SCM			27,892		26,831
RCM			43,090		41,035
Total deferred revenue			70,982		67,866
Notes payable			441,870		541,125
Bonds payable			325,000		325,000
Other liabilities
SCM			20,489		19,137
RCM			18,273		28,053
Corporate			172,972		160,206
Total other liabilities			211,734		207,396
Total liabilities		$	1,120,711	$	1,214,265
Segment Adjusted EBITDA to Consolidated Net Income	'
	The following table reconciles Segment Adjusted EBITDA to consolidated net income for the three months ended March 31, 2014 and 2013:
			Three Months Ended March 31,
			2014		2013
	SCM Adjusted EBITDA		$	49,950	$	53,712
	RCM Adjusted EBITDA			13,401		14,690
	Total Segment Adjusted EBITDA			63,351		68,402
	Depreciation			(8,262)		(6,476)
	Depreciation (included in cost of revenue)			(424)		(598)
	Amortization of intangibles			(14,026)		(16,501)
	Income tax expense			(16,390)		(13,910)
	Share-based compensation expense(1)			(2,098)		(1,398)
	Restructuring, acquisition and integration-related expenses(2)			(1,131)		(8,030)
	Total reportable segment net income			21,020		21,489
	Corporate net loss			(13,342)		(13,785)
	Consolidated net income		$	7,678	$	7,704
		-1	Represents non-cash share-based compensation to both employees and directors. We believe excluding this non-cash expense allows us to compare our operating performance without regard to the impact of share-based compensation, which varies from period to period based on amount and timing of grants.
		-2	Represents the amount attributable to restructuring, acquisition and integration-related costs which may include costs such as severance, retention, salaries relating to redundant positions, certain performance-related salary-based compensation, operating infrastructure costs and facility consolidation costs.

Business_Description_and_Basis2

Business Description and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'	'	'
Maturity period of liquid instruments	'Three months or less	'	'	'
Cash and cash equivalents	$0	$2,790	$8,532	$13,734
Revolving credit facility	26,245	26,245	'	'
Revolving credit facility	10,000	10,000	'	'
Outstanding checks recorded as accrued expenses	0	0	'	'
Outstanding checks related to a book overdraft into other accrued expenses	$14,846	'	'	'

Restructuring_Acquisition_and_1

Restructuring Acquisition and Integration-Related Expenses - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Business Combinations [Abstract]	'	'	'
Charges incurred	$1,697	$1,697	$8,030
Cash payments	'	1,382	'
Restructuring reserve current	'	$935	'

Deferred_Revenue_Summary_of_De

Deferred Revenue - Summary of Deferred Revenue (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue, total	$70,982	$62,892
Less: Deferred revenue, current portion	-54,498	-46,523
Deferred revenue, non-current portion	16,484	16,369
Software and Implementation Fees [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue, total	32,276	27,393
Service Fees [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue, total	24,617	22,363
Administrative Fees [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue, total	6,662	10,935
Other Fees [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue, total	$7,427	$2,201

Deferred_Revenue_Additional_In

Deferred Revenue - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Text Block [Abstract]	'	'
Contingent deferred revenue	$2,879	$6,516

Notes_and_Bonds_Payable_Summar

Notes and Bonds Payable - Summary of Notes Payable (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Total notes payable	$441,870	$439,500
Bonds payable	325,000	325,000
Total notes and bonds payable	766,870	764,500
Less: current portions	-33,308	-15,500
Total long-term notes and bonds payable	733,562	749,000
Term A Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Total notes payable	234,375	237,500
Total notes and bonds payable	234,375	'
Term B Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Total notes payable	181,250	192,000
Total notes and bonds payable	181,250	'
Revolving Credit Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Total notes payable	26,245	10,000
Total notes and bonds payable	$26,245	'

Notes_and_Bonds_Payable_Additi

Notes and Bonds Payable - Additional Information (Detail) (USD $)	3 Months Ended								3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Nov. 30, 2010
			Debt Instrument, Redemption, Period One [Member]	Maximum [Member]	Minimum [Member]	Revolving Credit Facility [Member]	Term B Facility [Member]	Term A Facility [Member]	Senior Notes Due 2018 [Member]	Senior Notes Due 2018 [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Notes payable	'	'	'	'	'	$26,245	$181,250	$234,375	'	'
Amount drawn on revolving credit facility	10,000	'	'	'	'	'	'	'	'	'
Revolving credit facility Swing line balance outstanding	16,245	'	'	'	'	'	'	'	'	'
Outstanding letter of credit under credit facility	172,755,000	'	'	'	'	'	'	'	'	'
Undrawn letters of credit outstanding amount	1,000,000	'	'	'	'	'	'	'	'	'
Maturity date of debt instrument	15-Nov-18	'	'	'	'	13-Dec-17	'	'	'	'
Scheduled principal payments	3,875,000	'	'	'	'	'	'	'	'	'
Voluntary prepayment on Term B Facility	'	'	'	'	'	'	10,000,000	'	'	'
Weighted average interest rate of senior term loan facility	'	'	'	'	'	2.49%	4.00%	2.50%	'	'
Percentage of consolidated tangible assets and revenues of subsidiaries not providing guarantees	'	'	'	2.50%	'	'	'	'	'	'
Percentage of consolidated earnings before interest taxes depreciation and amortization on consolidated basis of immaterial subsidiaries not providing guarantees	'	'	'	'	5.00%	'	'	'	'	'
Percentage of pledged equity securities of foreign subsidiary	65.00%	'	'	'	'	'	'	'	'	'
Principal amount of senior notes	'	'	'	'	'	'	'	'	'	325,000,000
Percentage owned by subsidiary guarantor	'	'	'	'	'	'	'	'	100.00%	'
Percentage of interest rate on bonds payable	8.00%	'	'	'	'	'	'	'	'	'
Percentage of principal amount for Redemption price	'	'	100.00%	'	'	'	'	'	'	'
Repurchase percentage of aggregate principal amount plus accrued and unpaid interest	'	'	'	'	'	'	'	'	101.00%	'
Percentage of par value on senior notes	'	'	'	'	'	'	'	'	107.00%	'
Debt issuance costs	16,323,000	'	'	'	'	'	'	'	'	'
Amortization of debt issuance costs	943,000	953,000	'	'	'	'	'	'	'	'
Total interest paid	$3,484,000	$5,932,000	'	'	'	'	'	'	'	'

Notes_and_Bonds_Payable_Percen

Notes and Bonds Payable - Percentage of Redemption Prices (Detail) (Senior Notes Due 2018 [Member])	3 Months Ended
	Mar. 31, 2014
Senior Notes Due 2018 [Member]	'
Debt Instrument [Line Items]	'
2014	104.00%
2015	102.00%
2016 and thereafter	100.00%

Notes_and_Bonds_Payable_Debt_M

Notes and Bonds Payable - Debt Maturities and Scheduled Principal Repayments (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Principal Payment in 2014	$27,870	'
Principal Payment in 2015	21,750	'
Principal Payment in 2016	28,000	'
Principal Payment in 2017	194,250	'
Principal Payment in 2018	328,000	'
Thereafter	167,000	'
Total notes and bonds payable	766,870	764,500
Term A Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Payment in 2014	9,375	'
Principal Payment in 2015	18,750	'
Principal Payment in 2016	25,000	'
Principal Payment in 2017	181,250	'
Total notes and bonds payable	234,375	'
Term B Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Payment in 2014	2,250	'
Principal Payment in 2015	3,000	'
Principal Payment in 2016	3,000	'
Principal Payment in 2017	3,000	'
Principal Payment in 2018	3,000	'
Thereafter	167,000	'
Total notes and bonds payable	181,250	'
Revolving Credit Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Payment in 2014	16,245	'
Principal Payment in 2017	10,000	'
Total notes and bonds payable	26,245	'
Senior Unsecured Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Payment in 2018	325,000	'
Total notes and bonds payable	$325,000	'

Stockholders_Equity_and_ShareB2

Stockholders' Equity and Share-Based Compensation - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

In Thousands, except Share data, unless otherwise specified

Feb. 26, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2010

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Plans

SSARS Awards [Member]

Restricted Common Stock Awards [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Restricted Stock [Member]

Performance-Based Restricted Shares [Member]

Performance-Based Restricted Shares [Member]

Performance-Based Restricted Shares [Member]

Performance-Based Restricted Shares Using EBITDA Performance Metric [Member]

Performance-Based Restricted Shares Using EBITDA Performance Metric [Member]

Performance-Based Restricted Shares Using EBITDA Performance Metric [Member]

Service-Based Restricted Shares Vesting Each Month Through December 31, 2013 [Member]

Service-Based Restricted Shares [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued in connection with exercise of stock options

'

'

'

211,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate exercise price of stock issued in connection with exercise of stock options

'

$1,756

'

$1,756

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited, Shares

'

'

'

'

26,000

'

'

'

'

'

'

'

'

'

'

'

'

Restricted shares that surrendered from equity awards holders

'

'

'

'

'

'

'

'

109,000

'

'

'

'

'

'

'

'

Associated minimum statutory tax liability, shares surrendered

'

'

'

'

'

'

'

'

2,623

'

'

'

'

'

'

'

'

Authorized amount for share repurchase program, maximum

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares reserved under 2008 equity incentive plan available for grant

'

4,800,000

'

'

'

500,000

'

'

1,218,826

343,230

'

'

343,230

'

'

63,355

469,011

Number of share based compensation plans

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

'

4,302

3,411

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income tax benefit recognized from equity awards

'

1,602

1,280

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capitalized share-based compensation expenses

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of price per share of the common stock sold to participating employees

'

'

'

'

'

'

'

95.00%

'

'

'

'

'

'

'

'

'

Period required for holding stock purchases as per the plan

'

'

'

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock purchased

'

'

'

'

'

11,000

11,700

'

'

'

'

'

'

'

'

'

'

Shares of common stock purchased, amount

'

'

'

'

'

$253

$205

'

'

'

'

'

'

'

'

'

'

Weighted average grant date fair value, Granted

'

'

'

'

'

'

'

'

$25.06

'

'

'

'

'

'

'

'

Share-based payment award, award vesting period

'

'

'

'

'

'

'

'

'

'3 years

'

'

'3 years

'

'

'

'3 years

Percentage to earn from performance-based equity awards

'

'

'

'

'

'

'

'

'

'

50.00%

100.00%

'

50.00%

100.00%

'

'

Stockholders_Equity_and_ShareB3

Stockholders' Equity and Share-Based Compensation - Summary of Amount and Cost of Common Stock Repurchased (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Equity [Abstract]	'	'
Number of shares repurchased	640,000	'
Cost of shares repurchased	$16,061	'

Stockholders_Equity_and_ShareB4

Stockholders' Equity and Share-Based Compensation - Summary of Amount and Cost of Common Stock Repurchased (Parenthetical) (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Equity [Abstract]	'
Number of cash settlement days	'3 days
Shares purchased	120,000
Shares purchased, value	$2,954

Stockholders_Equity_and_ShareB5

Stockholders' Equity and Share-Based Compensation - Summary of Total Share-Based Compensation Expense (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Shareholders Equity And Share Based Payments [Line Items]	'	'
Total share-based compensation expense	$4,302	$3,411
Cost of Revenue [Member]	'	'
Shareholders Equity And Share Based Payments [Line Items]	'	'
Total share-based compensation expense	1,166	713
Product Development [Member]	'	'
Shareholders Equity And Share Based Payments [Line Items]	'	'
Total share-based compensation expense	244	118
Selling and Marketing [Member]	'	'
Shareholders Equity And Share Based Payments [Line Items]	'	'
Total share-based compensation expense	527	379
General and Administrative [Member]	'	'
Shareholders Equity And Share Based Payments [Line Items]	'	'
Total share-based compensation expense	$2,365	$2,201

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Effective income tax rate	43.80%	39.30%

Income_Per_Share_Reconciliatio

Income Per Share - Reconciliation of Basic and Diluted Weighted Average Shares Outstanding (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Numerator for Basic and Diluted Income Per Share:	'	'
Net income	$7,678	$7,704
Denominator for basic income per share weighted average shares	60,648,000	59,006,000
Effect of dilutive securities:	'	'
Stock options	285,000	719,000
SSARs	327,000	345,000
Restricted stock and RSUs	421,000	334,000
Denominator for diluted income per share-adjusted weighted average shares and assumed conversions	61,681,000	60,404,000
Basic income per share:	'	'
Basic net income from continuing operations	$0.13	$0.13
Diluted net income per share:	'	'
Diluted net income from continuing operations	$0.12	$0.13

Income_Per_Share_Summary_of_Po

Income Per Share - Summary of Potentially Dilutive Securities (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
SSARs	327,000	345,000
Stock Appreciation Rights (SARs) [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
SSARs	'	63,000

Segment_Information_Additional

Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
	Segment
Segment Reporting [Abstract]	'
Number of reportable business segments	2

Segment_Information_Financial_

Segment Information - Financial Information of Business Segments (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Revenue:	'	'	'
Administrative fees, net	$76,246,000	$76,519,000	'
Other service fees	94,621,000	96,318,000	'
Total net revenue	170,867,000	172,837,000	'
Operating expenses:	'	'	'
Total operating expenses	146,087,000	148,839,000	'
Operating income (loss):	'	'	'
Total operating income	24,780,000	23,998,000	'
Interest expense	-11,173,000	-11,349,000	'
Other income	58,000	41,000	'
Income before income taxes	13,665,000	12,690,000	'
Income tax expense	5,987,000	4,986,000	'
Net income	7,678,000	7,704,000	'
Total Segment Adjusted EBITDA	63,351,000	68,402,000	'
Capital expenditures :	'	'	'
Total Capital expenditures	1,748,000	686,000	'
Accounts receivable, net	'	'	'
Total accounts receivable, net	100,993,000	'	87,636,000
Other assets	'	'	'
Total assets	1,606,619,000	'	1,613,749,000
SCM accrued revenue share obligation	71,125,000	'	77,398,000
Deferred revenue	'	'	'
Total deferred revenue	70,982,000	'	62,892,000
Bonds payable	325,000,000	'	325,000,000
Other liabilities	'	'	'
Total liabilities	1,120,711,000	'	1,123,960,000
Operating Segments [Member]	'	'	'
Revenue:	'	'	'
Total net revenue	170,867,000	172,837,000	'
Operating expenses:	'	'	'
Total operating expenses	146,087,000	148,839,000	'
Operating income (loss):	'	'	'
Total operating income	24,780,000	23,998,000	'
Interest expense	-11,173,000	-11,349,000	'
Other income	58,000	41,000	'
Income before income taxes	13,665,000	12,690,000	'
Income tax expense	5,987,000	4,986,000	'
Net income	7,678,000	7,704,000	'
Total Segment Adjusted EBITDA	63,351,000	68,402,000	'
Total Adjusted EBITDA	56,717,000	61,646,000	'
Capital expenditures :	'	'	'
Total Capital expenditures	10,131,000	8,978,000	'
Accounts receivable, net	'	'	'
Total accounts receivable, net	100,993,000	93,660,000	'
Other assets	'	'	'
Total other assets	1,505,626,000	1,569,640,000	'
Total assets	1,606,619,000	1,663,300,000	'
SCM accrued revenue share obligation	71,125,000	72,878,000	'
Deferred revenue	'	'	'
Total deferred revenue	70,982,000	67,866,000	'
Notes payable	441,870,000	541,125,000	'
Bonds payable	325,000,000	325,000,000	'
Other liabilities	'	'	'
Total other liabilities	211,734,000	207,396,000	'
Total liabilities	1,120,711,000	1,214,265,000	'
SCM [Member]	'	'	'
Operating income (loss):	'	'	'
Total Segment Adjusted EBITDA	49,950,000	53,712,000	'
SCM [Member] | Operating Segments [Member]	'	'	'
Revenue:	'	'	'
Gross administrative fees	126,361,000	120,636,000	'
Revenue share obligation	-50,115,000	-44,117,000	'
Administrative fees, net	76,246,000	76,519,000	'
Other service fees	32,371,000	32,989,000	'
Total net revenue	108,617,000	109,508,000	'
Operating expenses:	'	'	'
Total operating expenses	76,443,000	81,689,000	'
Operating income (loss):	'	'	'
Total operating income	32,174,000	27,819,000	'
Total Adjusted EBITDA	49,950,000	53,712,000	'
Capital expenditures :	'	'	'
Total Capital expenditures	3,283,000	1,857,000	'
Accounts receivable, net	'	'	'
Total accounts receivable, net	50,510,000	45,613,000	'
Other assets	'	'	'
Total other assets	943,587,000	995,161,000	'
Deferred revenue	'	'	'
Total deferred revenue	27,892,000	26,831,000	'
Other liabilities	'	'	'
Total other liabilities	20,489,000	19,137,000	'
RCM [Member]	'	'	'
Operating income (loss):	'	'	'
Total Segment Adjusted EBITDA	13,401,000	14,690,000	'
RCM [Member] | Operating Segments [Member]	'	'	'
Revenue:	'	'	'
Revenue cycle technology	44,193,000	43,381,000	'
Revenue cycle services	18,057,000	19,948,000	'
Total net revenue	62,250,000	63,329,000	'
Operating expenses:	'	'	'
Total operating expenses	56,975,000	55,693,000	'
Operating income (loss):	'	'	'
Total operating income	5,275,000	7,636,000	'
Total Adjusted EBITDA	13,401,000	14,690,000	'
Capital expenditures :	'	'	'
Total Capital expenditures	5,499,000	5,149,000	'
Accounts receivable, net	'	'	'
Total accounts receivable, net	50,348,000	48,047,000	'
Other assets	'	'	'
Total other assets	496,577,000	489,967,000	'
Deferred revenue	'	'	'
Total deferred revenue	43,090,000	41,035,000	'
Other liabilities	'	'	'
Total other liabilities	18,273,000	28,053,000	'
Corporate [Member]	'	'	'
Operating income (loss):	'	'	'
Net income	-13,342,000	-13,785,000	'
Corporate [Member] | Operating Segments [Member]	'	'	'
Operating expenses:	'	'	'
Total operating expenses	12,669,000	11,457,000	'
Operating income (loss):	'	'	'
Total operating income	-12,669,000	-11,457,000	'
Total Adjusted EBITDA	-6,634,000	-6,756,000	'
Capital expenditures :	'	'	'
Total Capital expenditures	1,349,000	1,972,000	'
Accounts receivable, net	'	'	'
Total accounts receivable, net	135,000	'	'
Other assets	'	'	'
Total other assets	65,462,000	84,512,000	'
Other liabilities	'	'	'
Total other liabilities	$172,972,000	$160,206,000	'

Segment_Information_Segment_Ad

Segment Information - Segment Adjusted Ebitda Consolidated Net Income (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Total Segment Adjusted EBITDA	$63,351	$68,402
Depreciation	-11,540	-9,177
Net (loss) income	7,678	7,704
Amortization of intangibles	-14,026	-16,501
Income tax expense	-5,987	-4,986
Share-based compensation expense	-4,302	-3,411
SCM [Member]	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Total Segment Adjusted EBITDA	49,950	53,712
RCM [Member]	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Total Segment Adjusted EBITDA	13,401	14,690
Segment Reporting Reconciling Items [Member]	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Depreciation	-8,262	-6,476
Depreciation (included in cost of revenue)	-424	-598
Amortization of intangibles	-14,026	-16,501
Income tax expense	-16,390	-13,910
Share-based compensation expense	-2,098	-1,398
Restructuring, acquisition and integration-related expenses	-1,131	-8,030
Reportable Segment [Member]	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Net (loss) income	21,020	21,489
Corporate [Member]	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'
Net (loss) income	($13,342)	($13,785)

Related_Party_Transaction_Addi

Related Party Transaction - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Related Party Transactions [Abstract]	'	'
Charges incurred with respect to transactions with Mr. Bardis	$378	$587